It is thus logical to suggest that both wild-type and mutant p53 can induce galectin-7 in breast cancer cells, but given the intrinsic resistance of these cells to cell death, the balance is shifted towards the protumorigenic role of galectin-7 (Figure 2). This evidence concerns the gene TP53 and breast cancer.